32 new drugs approved in Shanghai last year

2006, the annual industrial output value of Shanghai Biopharmaceuticals exceeded 30 billion yuan, and itschinese medicinetreatment equipment output value of nearly 10 billion yuan2006 was a crucial year for the launch of the 11th Five-Year PlanOver the past year, Shanghai Biomedicine has made great achievements in structural adjustment, planning strategic layout and promoting industrial developmentThere are 446 biopharmaceutical enterprises in Shanghai, including 46 large and medium-sized enterprises such as Shanghai Pharmaceutical Group and Fosun Pharma, and 9 domestic and foreign listed biopharmaceutical enterprisesLast year, the production of key enterprises in Shanghai biopharmaceuticalbegan to grow steadily, and after several years of adjustment, three leading enterprises, namely Shanghai Pharmaceuticals, Fosun and Shanghai, showed a steady growth trend;At the same time, a number of key support of the advantages of enterprises to accelerate the pace of internationalizationAccording to statistics, from January to October 2006, the total exports of Shanghai's biopharmaceutical industry amounted to 4.101 billion yuan, an increase of 31.78 percent year-on-yearExport products also from the bulk of raw materials, low-end disposablemedical devicesmainly gradually to high value-added productsShanghai Science and Technology Commission, The National Development and Reform Commission, foodpharmaceuticalRegulatory Authority in 2006 around the national strategy and the needs of the Shanghai biopharmaceutical industry development, organized the implementation of a number of cutting-edge science and technology projects, to promote the construction of new drug screening centers, safety evaluation centers and drug testing centers and other public service platforms, while starting to build a number of new public service platforms, such as pharmaceutical replacement centers, experimental animal centers and clinical trial institutions, for the Shanghai biopharmaceutical industry continued innovation and accumulation of potentialIn 2006, there were 4 national "973" projects, 24 "863" major and key projects, and 6 projects on the internationalization of Chinese medicineFrom January to November 2006, in the field of life science, Shanghai scientists published 4 papers in science, 1 in Nature, 7 papers in nature, nature biotechnology, natural cell biology and natural genetics, accounting for 29% of the country The number of patents in the field of biomedicine in the city is 2005 Thirty-two new drugs were approved for production and 74 new drugs were approved for clinical study, including 9 innovative drugs produced and developed by local enterprises In October 2006, the National Development and Reform Commission approved the construction of Shanghai's national bio-industry base, which provides new opportunities for the development of Shanghai's biopharmaceutical industry It is reported that in 2007, Shanghai will further enhance the independent innovation ability and core competitiveness of the biopharmaceutical industry, and strive to make the Shanghai biopharmaceutical industry to a new level, biopharmaceutical manufacturing output value exceeded 35 billion yuan Link Shanghai with the "dumbbell model" to develop new drugs Shanghai research and development, overseas clinical - this "one end, the other side outside" "dumbbell model", is becoming Shanghai's new drugs to the international market fast track Shencheng a number of independent innovative drugs have entered the foreign clinical research, of which, the Chinese Academy of Sciences Shanghai Drug development of the treatment of Alzheimer's innovative drug Shiplin has started three phases of clinical in Europe, is expected to be approved for listing in two years In addition to Shiplin, the international express train is also the Zesheng biological treatment of heart failure of a class of new drug recombination new person Newland Green, and Huang Pharmaceutical's Chinese medicine HMPL-002 and 004 and so on At present, these innovative drugs are conducted in Australia, Europe and the United States and other countries and regions of clinical research, if successfuloverseas listing, will enhance the Shanghai biopharmaceutical industry to participate in international competition (reproduced from healthnews.com)